Clinical trials: Pheochromocytoma and Paraganglioma (PPGL), active
Primary Aldosteronism, Adrenal Tumor
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery.
- Conditions
- Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT07182175
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
Pheochromocytoma and Paraganglioma (PPGL), Adrenocorticol Cancer (ACC)
National Study of Adrenal Tumours
This is a study putting together large numbers of patients with or without a hereditary risk of adrenal tumours including tumours such as adrenocortical carcinoma and phaeochromocytoma/paraganglioma.
- Conditions
- Pheochromocytoma and Paraganglioma (PPGL), Adrenocorticol Cancer (ACC), Adrenal Tumours
- Trial name
- NSAT (NCT06870396)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Society for Endocrinology
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types.
- Conditions
- Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT06503146
- Testing
- [18F]FAPI-74, [18F]FDG
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Cancer Institute (NCI)
Pheochromocytomas, Paragangliomas
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL).
- Trial name
- PRRT-PGL-PHEO (NCT07538791)
- Testing
- Peptide Receptor Radionuclide Therapy (PRRT)
- Where
- 10 sites in Italy
- Volunteers
- 210 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Pheochromocytoma/Paraganglioma (PPGL)
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-LM3 PET/CT and compare it with 68Ga-DOTATATE PET/CT in patients with pheochromocytoma/paraganglioma (PPGL).
- Trial name
- NCT07288931
- Testing
- Diagnostic Test: Al18F-NOTA-LM3, Diagnostic Test: 68Ga-DOTATATE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'.
- Conditions
- Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma
- Trial name
- NCT07680205
- Testing
- Belzutifan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Pheochromocytoma and Paraganglioma (PPGL)
Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)
It is preliminarily clarified that belzutifan exerts an inhibitory effect on catecholamine synthesis in pheochromocytoma and paraganglioma (PPGL), and its safety is simultaneously confirmed, thereby providing preliminary…
- Trial name
- NCT07907341
- Testing
- Belzutifan
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Longfei Liu，MD
Cushing s Syndrome, Cushing Disease
Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)
Primary Objective: The primary objective of the study is to characterize subjects affected by adrenal disease by collecting medical history data at diagnosis, clinical, bio-humoral, and radiological data, as well as information…
- Conditions
- Cushing s Syndrome, Cushing Disease, Cushing Disease Due to Increased ACTH Secretion, Mild Autonomous Cortisol Secretion (MACS)
- Trial name
- ADRENALINK (NCT07920198)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Adrenocortical Carcinoma, Pheochromocytoma
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT07743138
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center